Cargando…

Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients

INTRODUCTION: Systemic lupus erythematosus (SLE) patients have lower bone mineral density and increased fracture risk when compared with healthy individuals, due to distinct factors and mechanisms. Bone remodeling is a tightly orchestrated process dependent on several factors, including the balance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carmona-Fernandes, Diana, Santos, Maria José, Perpétuo, Inês Pedro, Fonseca, João Eurico, Canhão, Helena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308110/ https://www.ncbi.nlm.nih.gov/pubmed/22027240 http://dx.doi.org/10.1186/ar3500

Ejemplares similares

Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile
por: Carmona-Fernandes, Diana, et al.
Publicado: (2013)

Salivary soluble receptor activator of nuclear factor kappa B ligand/osteoprotegerin ratio in periodontal disease and health
por: Tabari, Zahra Alizadeh, et al.
Publicado: (2013)

Platelet-rich fibrin increases the osteoprotegerin/receptor activator of nuclear factor-κB ligand ratio in osteoblasts
por: Sumida, Ryuta, et al.
Publicado: (2019)

Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor-κβ expression in monocytes from patients with early rheumatoid arthritis
por: Perpétuo, Inês Pedro, et al.
Publicado: (2017)

Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus
por: Lambrinoudaki, Irene, et al.
Publicado: (2013)

Effects of High and Low Doses of Folic Acid on the Soluble Receptor Activator of Nuclear Factor-kappa B Ligand/Osteoprotegerin Ratio during Pregnancy
por: FATHI MAROUFI, Nazila, et al.
Publicado: (2017)

Increase in receptor activator of nuclear factor κB ligand/osteoprotegerin ratio in peri-implant gingiva exposed to Porphyromonas gingivalis lipopolysaccharide
por: Shuto, Takahiro, et al.
Publicado: (2016)

Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
por: Trouvin, Anne-Priscille, et al.
Publicado: (2010)

Osteoprotegerin/receptor activator of nuclear factor-κB ligand are involved in periodontitis-promoted vascular calcification
por: Jiao, Mengyu, et al.
Publicado: (2022)

Effect of Breastfeeding on Serum Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-Kappa B Ligand in Full Term Neonates
por: Rafeey, Mandana, et al.
Publicado: (2013)

Production of Soluble Receptor Activator of Nuclear Factor Kappa-Β Ligand and Osteoprotegerin by Apical Periodontitis Cells in Culture and Their Modulation by Cytokines
por: Duka, Miloš, et al.
Publicado: (2019)

Effect of gallium nitrate on the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand in osteoblasts in vivo and in vitro
por: LI, JINGWU, et al.
Publicado: (2016)

Early Vascular Alterations in SLE and RA Patients—A Step towards Understanding the Associated Cardiovascular Risk
por: Santos, Maria José, et al.
Publicado: (2012)

Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?
por: Romão, Vasco Crispim, et al.
Publicado: (2013)

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2020)

Response measures influence comparative effectiveness of biological drugs in rheumatoid arthritis
por: Canhao, Helena, et al.
Publicado: (2012)

Expression of osteoprotegerin and osteoprotegerin ligand in giant cell tumor of bone and its clinical significance
por: YU, XIUCHUN, et al.
Publicado: (2013)

Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease
por: Ugay, Ludmila, et al.
Publicado: (2016)

Imbalance of osteoprotegerin/receptor activator of nuclear factor-κB ligand and oxidative stress in patients with obstructive sleep apnea-hypopnea syndrome
por: Ma, Xiao-Rong, et al.
Publicado: (2019)

The Role of Osteoprotegerin and Its Ligands in Vascular Function
por: Rochette, Luc, et al.
Publicado: (2019)

Receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in gingival crevicular fluid
por: Sarlati, Fatemeh, et al.
Publicado: (2012)

Validity of Osteoprotegerin and Receptor Activator of NF-κB Ligand for the Detection of Bone Metastasis in Breast Cancer
por: Elfar, Gamal A., et al.
Publicado: (2017)

Isoliquiritigenin Inhibits Metastatic Breast Cancer Cell-induced Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Human Osteoblastic Cells
por: Lee, Sun Kyoung, et al.
Publicado: (2015)

Mycophenolate mofetil use in refractory juvenile systemic lupus erythematosus
por: Marques, R, et al.
Publicado: (2010)

The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts
por: Burgess, Teresa L., et al.
Publicado: (1999)

Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin
por: Zauli, Giorgio, et al.
Publicado: (2008)

Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis
por: Giaginis, Constantinos, et al.
Publicado: (2012)

Mycobacterium tuberculosis 10-kDa co-chaperonin regulates the expression levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in human osteoblasts
por: ZHANG, YUANYU, et al.
Publicado: (2015)

Upregulation of Inflammatory Genes and Downregulation of Sclerostin Gene Expression Are Key Elements in the Early Phase of Fragility Fracture Healing
por: Caetano-Lopes, Joana, et al.
Publicado: (2011)

Increased concentration of serum soluble LAG3 in systemic lupus erythematosus
por: Yu, Seri, et al.
Publicado: (2012)

IL-1 family cytokines and soluble receptors in systemic lupus erythematosus
por: Italiani, Paola, et al.
Publicado: (2018)

Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study
por: Lien, Gunhild, et al.
Publicado: (2010)

Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
por: Park, Hye-Rim, et al.
Publicado: (2003)

Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis
por: Remuzgo-Martínez, Sara, et al.
Publicado: (2016)

Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis
por: Perpétuo, Inês P., et al.
Publicado: (2017)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
por: Widschwendter, Martin, et al.
Publicado: (2015)

Elevated levels of soluble intercellular adhesion molecule -1 in systemic lupus erythematosus
por: Kljukvina, N, et al.
Publicado: (2001)

Decreased serum level of soluble-leptin-receptor in patients with systemic lupus erythematosus
por: Bagheri, K, et al.
Publicado: (2012)

Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Ankylosing Spondylitis
por: Perpétuo, Inês P., et al.
Publicado: (2015)

Ankylosing Spondylitis Patients Have Impaired Osteoclast Gene Expression in Circulating Osteoclast Precursors
por: Perpétuo, Inês P., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eio5qamacvssmm7353vu6rqjov